T27 Silicoin (T27S)

Real estate investment opportunity in the heart of Silicon Valley

Review Score
N/A
ICO Price
1 USD
Pre ICO Price
N/A
Soft Cap
5000000 USD
Hard Cap
100000000 USD
Start Date
1 October 2021
End Date
30 September 2022

What is T27 Silicoin?

 

T27 Silicoin is the security token of Tower 27 which is destined to become one of the most valuable commercial properties in Silicon Valley’s city center, downtown San Jose. T27 Silicoin Security Token Offering is one of the largest single real estate STOs in the world with $100 million in size.

T27 Silicoin is a Silicon Valley real estate security token backed by the equities of Tower 27 Partners LP, a Delaware limited partnership. Each T27 Silicoin Security Token (T27S) is a digital representation of a share in Tower 27 Partners, a limited partnership that owns the building and offers up to 12% annual interest plus 50% profit after the exit.

Net proceeds from the offering will be used for additional funding to develop the 24-story Class A multi-family building that features 374 residential units and 35,597 net square feet of second floor, mezzanine, and street-level commercial space. The property is fully entitled, and the construction is projected to start in the first quarter of 2022 to be completed within 32-months.

Information displayed on CoinCheckup can be updated by the respective ICOs and/or Crypto representatives and does not present the opinion of CoinCheckup.com and/or the CoinCheckup team.

Trading and investing in digital assets is highly speculative and comes with many risks. The analysis/stats on CoinCheckup.com and it’s subsites are for informational purposes and should not be considered investment advice and or the truth. Statements and financial information on CoinCheckup.com and it’s subsites should not be construed as an endorsement or recommendation to buy, sell or hold.

Please do your own research on all of your investments carefully. Scores are based on averages of third party websites.  Past performance is no indicative of future results. Read the full disclaimer here.